MTX injection not superior to oral administration in juvenile idiopathic arthritis
Injections of methotrexate were not superior to oral therapy in long-term treatment of patients with juvenile idiopathic arthritis, according to a new study, published in the May 30 online edition of Arthritis Care & Research.
Injections of methotrexate were not superior to oral therapy in long-term treatment of patients with juvenile idiopathic arthritis (JIA), according to a new study, published in the May 30 online edition of Arthritis Care & Research.
In the retrospective study, led by Araine Klein with Asklepios Klinik Sankt Augustin, in Germany, researchers reviewed 411 patients with JIA who received methotrexate (MTX) for at least 6 months. Patients in both the oral therapy and subcutaneous groups showed a high clinical response (73% for oral vs 72% for injection). In addition, 22% of patients who received oral MTX had at least 1 adverse event, compared to 27% in the subcutaneous group.
However, significantly more patients with subcutaneous application discontinued MTX because of adverse events (11%) compared to oral (5%).
“In this retrospective analysis, parenteral MTX was not superior to oral administration, regarding efficacy and tolerability,” the researchers wrote.
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
